MEDICREA Pursuing a Solid Increase in Sales

Share this story with your network

LYON, France–(BUSINESS WIRE)–The MEDICRA Group (Paris:ALMED), listed on Alternext by NYSE – Euronext Paris, a specialist in the design, manufacture and sale of spinal implants, is publishing its 2010 first quarter sales.

-> 21% increase in sales over the same period in 2009 (+25% at constant exchange rate):

Sales in M€ 2009 2010 Variance
1st Quarter 2.8 3.4 + 21%

The increase in sales should see a swift acceleration in the second half of 2010 due to the continued development of the Group’s distribution subsidiaries as well as the launch of new products in the US and European markets. The initial results of the pre-launch of the GRANVIA® cervical disc prosthesis, which started in early 2010 in selected hospitals in Europe, combined with a growing interest shown by surgeons, confirms the immense potential of the technique developed by MEDICREA. The full release of the GRANVIA® implant throughout Europe will start on July 1, 2010.

During Q1, new FDA clearances were obtained for MEDICREA’s innovative product line, all of which will be released onto the US market in the coming months. These latest clearances will be the subject of press releases in the coming weeks. The concept of the PASS-LP® posterior thoraco-lumbar fixation system is being expanded to offer anterior fixation. The first operation was recently performed, with successful results, in a highly renowned French hospital. The addition of an anterior thoraco-lumbar fixation system will complete MEDICREA’s product offering within the segment of complex spinal surgeries and allow MEDICREA to grab foothold in markets—especially Germany—where anterior surgery is already very popular.

COMING UP

2009 annual results will be published on April 26, 2010, after market closing, followed on July 9, 2010 by the release of the 2010 first semester sales.

ABOUT MEDICREA

MEDICREA specializes in the design, development, manufacture and distribution of orthopedic implants dedicated to spinal surgery. In an $8 billion market, growing at a rate of 10 to 15 % per annum, MEDICREA is a small to medium sized business of 90 employees with excellent reputation and unique relationships with the most visionary and creative spine surgeons in France, the U.K. and the U.S.A. Products developed and patented by MEDICREA provide surgeons with new and less invasive surgical solutions, which are faster and easier to implement than traditional techniques.

The Group operates from its headquarters based in Lyon, France with a manufacturing facility located in La Rochelle, France and three distribution subsidiaries in the U.S.A., U.K. and France.

Leave a Comment

Your email address will not be published. Required fields are marked *

*